AMGN•benzinga•
What's Going On With Amgen Stock On Friday?
Summary
Novo Nordisk's CagriSema shows 22.7% weight loss in Phase 3 trials, while tolerability concerns grow. MariTide offers competitive weight loss with less frequent dosing.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 20, 2024 by benzinga